What is the appropriate management of a patient presenting with purpura?

Management of Purpura

Initial Diagnostic Approach

The management of purpura depends critically on distinguishing between thrombocytopenic and non-thrombocytopenic causes, with immediate assessment of platelet count and peripheral blood smear being the essential first step. 1

Essential Initial Testing

• Obtain a complete blood count with platelet count and peripheral blood smear to confirm thrombocytopenia and exclude pseudothrombocytopenia 1
• Examine the peripheral blood smear for platelet size (normal or large platelets support ITP; giant platelets suggest alternative diagnosis), red blood cell morphology (schistocytes suggest TTP or DIC), and white blood cell abnormalities 2
• Measure prothrombin time and activated partial thromboplastin time to exclude coagulation factor deficiencies 3

Critical Distinction: Thrombocytopenic vs. Vasculitic Purpura

• Palpable purpura indicates cutaneous vasculitis (such as Henoch-Schönlein purpura or infection-related vasculitis) and requires different management than thrombocytopenic purpura 4, 5, 6
• Non-palpable purpura with thrombocytopenia suggests immune thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or other platelet disorders 7

Management Based on Platelet Count and Clinical Severity

Life-Threatening Bleeding (Any Platelet Count)

For patients with severe, life-threatening bleeding, immediately initiate combination therapy with platelet transfusions, high-dose parenteral glucocorticoids (30 mg/kg methylprednisolone daily for 3 days), and intravenous immunoglobulin (IVIg), along with conventional critical care measures. 2, 1

• This aggressive approach is justified despite lack of randomized trial evidence due to the serious consequences of severe hemorrhage 2
• Platelet transfusions are relatively contraindicated in TTP due to risk of precipitating thromboses; plasma exchange is the treatment of choice for TTP 8, 7

Platelet Count <20,000/μL

Treatment is mandatory for all patients with platelet counts <20,000/μL, even if asymptomatic. 8

• Initiate glucocorticoid therapy (prednisone 1-2 mg/kg/day) for adults with ITP 1
• Hospitalization is appropriate for children with platelet counts <20,000/μL and mucous membrane bleeding that may require clinical intervention 2, 1
• Prophylactic platelet transfusion is recommended at counts ≤10,000/μL in hospitalized patients with therapy-induced hypoproliferative thrombocytopenia to prevent spontaneous bleeding, which occurs in approximately 40% of patients at this level 8

Platelet Count 20,000-30,000/μL

Initiate treatment if the platelet count drops below 30,000/μL, particularly in symptomatic patients. 8, 1

• Glucocorticoid therapy (prednisone 1-2 mg/kg/day) is appropriate for adults with moderate thrombocytopenia and symptomatic purpura 1
• For children with only minor purpura and platelet counts in this range, observation without specific treatment may be appropriate, as spontaneous remission occurs in approximately 64-87% of untreated children 2

Platelet Count 30,000-50,000/μL

For adults with ITP and platelet counts <30,000/μL, initiate glucocorticoid therapy even in asymptomatic individuals. 8

• Do not withhold treatment for patients with platelet counts <50,000/μL who present with significant mucous membrane bleeding 1
• Patients with platelet counts >50,000/μL can safely undergo most invasive procedures without prophylactic platelet transfusion 1

Platelet Count >50,000/μL

• For major surgery, a platelet count >80,000/μL is generally considered safe 1
• Avoid unnecessary platelet transfusions for mild thrombocytopenia, as they provide no benefit and may lead to alloimmunization 1

Treatment Options for Chronic ITP

First-Line Therapy

Glucocorticoids remain the first-line treatment for ITP, but duration should be limited to avoid long-term side effects, particularly osteoporosis. 1

• Prednisone 1-2 mg/kg/day is the standard initial dose 1
• Most patients respond initially to steroids, but the disease generally relapses when steroids are tapered 7

Second-Line Therapy After Incomplete Response

For adults who have responded incompletely to prednisone and splenectomy, treatment selection depends on platelet count and bleeding symptoms. 2

For platelet counts <10,000/μL with bleeding symptoms, higher preference treatments include:

• Low-dose glucocorticoid 2
• IVIg 2
• High-dose glucocorticoid 2

For platelet counts 15,000-25,000/μL with bleeding symptoms, higher preference treatments include:

• IVIg 2
• Accessory splenectomy (if radioisotope scanning demonstrates probable accessory spleen) 2
• High-dose glucocorticoid 2

Splenectomy

Splenectomy offers a 70% chance of cure in chronic ITP and should be considered for patients with persistent disease after initial steroid therapy. 7

Novel Agents

Romiplostim (thrombopoietin receptor agonist) is effective for adults with ITP, with 61% of non-splenectomized patients and 38% of splenectomized patients achieving durable platelet response (weekly platelet count ≥50,000/μL for 6 of the last 8 weeks) 9

• Median weekly dose is 2-3 mcg/kg subcutaneously 9
• Significantly reduces need for rescue therapy (20-26% vs. 57-62% with placebo) 9

Special Considerations

Pediatric ITP

Most children with ITP (64-87%) experience spontaneous remission, with platelet counts normalizing in 2-8 weeks. 2

• Observation without treatment is appropriate for children with only minor purpura, as the risk of fatal intracranial hemorrhage is low (0.5%) 2
• Emergency treatment is indicated for severe, life-threatening bleeding regardless of platelet count 2
• Hospitalization is inappropriate for children with platelet counts >30,000/μL who are asymptomatic or have only minor purpura 2

Congenital Purpura Fulminans

For pediatric patients with congenital purpura fulminans due to homozygous protein C deficiency, protein C replacement is preferred over anticoagulation alone for long-term management. 2

• Protein C replacement has superior long-term effectiveness without the bleeding risk of anticoagulation 2
• For acute episodes, combination therapy with protein C replacement plus anticoagulation is preferred over anticoagulation alone 2
• Liver transplantation is curative but has significant acute and chronic risks; the optimal therapy depends on family values and local health service factors 2

Vasculitic Purpura (Henoch-Schönlein Purpura)

Henoch-Schönlein purpura spontaneously resolves in 94% of children and 89% of adults, making supportive treatment the primary intervention. 6

• Oral prednisone 1-2 mg/kg daily for two weeks can be used to treat abdominal and joint symptoms 6
• Corticosteroid use in children reduces the mean time to resolution of abdominal pain and decreases the odds of developing persistent renal disease 6
• Early aggressive therapy with high-dose steroids plus immunosuppressants is recommended for patients with severe renal involvement 6

Infection-Related Vasculitis

In any febrile patient with palpable purpura, particularly with a cardiac murmur, obtain blood cultures to exclude bacterial endocarditis. 5

• The infectious origin is demonstrated in less than 30% of cases of leukocytoclastic vasculitis 5
• Consider viral causes (hepatitis B and C, cytomegalovirus, parvovirus), as antiviral treatment permits better control of vasculitis 5

Common Pitfalls to Avoid

• Never withhold treatment for patients with platelet counts <20,000/μL regardless of symptoms 8
• Do not transfuse platelets in suspected TTP, as this may precipitate thromboses; initiate plasma exchange instead 8, 7
• Do not assume all purpura is thrombocytopenic; palpable purpura indicates vasculitis requiring different management 4, 5
• Consider coexisting conditions such as platelet dysfunction, coagulation abnormalities (DIC, liver disease), or lifestyle factors that may require higher transfusion thresholds 8
• Limit glucocorticoid duration to avoid long-term complications, particularly osteoporosis 1